PHOENIX-OITB – A single entry point to develop and upgrade innovative nanopharmaceuticals
Creators
- 1. BioNanoNet Forschungsgesellschaft mbH; Grace Bio S.L, Barcelona, Spain
- 2. Nanomol Technologies S.L Barcelona, Spain
- 3. Leanbio S.L, Barcelona, Spain,
- 4. Consejo Superior de Investigaciones Cientificas (ICMAB), Spain
- 5. Institute for Medical Research and Occupational Health
- 6. Research Center for Pharmaceutical Engineering GmbH, Graz, Austria
- 7. Cenya Imaging B.V.
- 8. Topas Therapeutics GmbH
- 9. Research Center for Non-Destructive Testing GmbH, Linz, Austria
- 10. The Luxembourg Institute of Science and Technology, Luxembourg
- 11. MyBiotech GmbH, Überherrn, Germany
Description
The PHOENIX Open Innovation Test Bed (PHOENIX-OITB) is focused on overcoming the challenges of production of novel and innovative nanopharmaceuticals (NPs) from lab scale to GMP quality and production, maximising bioavailability, stability and manufacturing to allow their implementation in the medicine field.
PHOENIX-OITB is a non-profit, open and self-sustaining legal entity that works as a Single-Entry-Point (SEP) providing its end-users transparent processes and procedures as well as easy access to services and expertise needed to bridge the gap between the bench and the bedside, i.e., providing them with high-quality services, capable of Quality-Efficacy and Safety (QES) evaluation and production of nanopharmaceuticals at large scales meeting the regulatory and GMP requirements.
Files
PHOENIX_Poster_2023.pdf
Files
(887.9 kB)
| Name | Size | Download all |
|---|---|---|
|
md5:ac970f549cecd5ff1e2349e8853cab78
|
887.9 kB | Preview Download |